Clearside Biomedical

Clearside BioMedical, an ophthalmic company, specializes in the research, development, and commercialization of therapeutic products through an ocular microinjection platform that targets the individual compartments of the eye. It provides a non-surgical application for dosing drugs to distinct eye tissues, such as the retina, trabecular meshwork, and corneal stroma. The company’s CLS1001 is under development for retinal applications through the delivery of therapeutics to the suprachoroidal space. Clearside BioMedical was incorporated in 2011 and is based in Atlanta, Georgia.

Clearside Biomedical headquartered in United States, North America, operates in the Biotechnology, Health Care, Pharmaceutical, Medical Device, Therapeutics sector. The company focuses on Biotechnology and has secured $32.6B in funding across 160 round(s). With a team of 11-50 employees, Clearside Biomedical is actively contributing to advancements in Biotechnology. Their latest funding round, Series A - Clearside Biomedical, raised $4.0M. Discover more about their projects, partnerships, and impact on our platform.